ENG

Chr 9AD

endoglin

Also known as: END, HHT1, ORW1

This gene encodes a homodimeric transmembrane protein which is a major glycoprotein of the vascular endothelium. This protein is a component of the transforming growth factor beta receptor complex and it binds to the beta1 and beta3 peptides with high affinity. Mutations in this gene cause hereditary hemorrhagic telangiectasia, also known as Osler-Rendu-Weber syndrome 1, an autosomal dominant multisystemic vascular dysplasia. This gene may also be involved in preeclampsia and several types of cancer. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2013]

Primary Disease Associations & Inheritance

Telangiectasia, hereditary hemorrhagic, type 1MIM #187300
AD
490
ClinVar variants
125
Pathogenic / LP
1.00
pLI score· haploinsufficient
12
Active trials
Clinical SummaryENG
🧬
Gene-Disease Validity (ClinGen)
juvenile polyposis syndrome · ADLimited

Limited evidence — not for standalone diagnostic reporting

2 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
125 Pathogenic / Likely Pathogenic· 125 VUS of 490 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.24LOEUF
pLI 0.999
Z-score 4.78
OE 0.09 (0.040.24)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
0.93Z-score
OE missense 0.87 (0.790.95)
338 obs / 389.9 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.09 (0.040.24)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.87 (0.790.95)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.02
01.21.6
LoF obs/exp: 3 / 32.3Missense obs/exp: 338 / 389.9Syn Z: -0.25

ClinVar Variant Classifications

490 submitted variants in ClinVar

Classification Summary

Pathogenic94
Likely Pathogenic31
VUS125
Likely Benign230
Benign5
Conflicting5
94
Pathogenic
31
Likely Pathogenic
125
VUS
230
Likely Benign
5
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
61
2
31
0
94
Likely Pathogenic
20
8
3
0
31
VUS
2
82
40
1
125
Likely Benign
0
13
46
171
230
Benign
0
3
2
0
5
Conflicting
5
Total83108122172490

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

ENG · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

ENG-related hereditary haemorrhagic telangiectasia

definitive
ADLoss Of FunctionAbsent Gene Product
Skin
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

ENDOGLIN; ENG
MIM #131195 · *

Telangiectasia, hereditary hemorrhagic, type 1

MIM #187300

Molecular basis of disorder known

Autosomal dominant
📖
GeneReview available — ENG
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
Hereditary haemorrhagic telangiectasia.
Hermann R et al.·Nat Rev Dis Primers
2025Review
GFAP at 50.
Messing A et al.·ASN Neuro
2020Review
DISENGAGE Registry.
Pellicano M et al.·Circ Cardiovasc Interv
2020
Endoglin-targeted cancer therapy.
Seon BK et al.·Curr Drug Deliv
2011Review
Inner ear disorders.
Smouha E·NeuroRehabilitation
2013Review
Videonystagmography and Posturography.
Falls C·Adv Otorhinolaryngol
2019Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Hot FlashesMenopause Surgical

Acupuncture With/Without Self-acupressure for Post-oophorectomy Hot Flashes in BRCA Carriers

NOT YET RECRUITING
NCT05331209Phase NAShaare Zedek Medical CenterStarted 2026-01-01
AcupunctureAcupuncture-Acupressure
Cancer EducationSpanish Language Cancer Education

Outreach Core Activities

RECRUITING
NCT05832177H. Lee Moffitt Cancer Center and Research InstituteStarted 2023-03-22
Cancer CientoUno (101) programLatinos y el cáncer/Hablemos de cáncer (Translation in English: Latinos and Cancer/Let's Talk About Cancer)¡Salud! Serie de Charlas (Translation in English: Health! Talk Series)
Hereditary Hemorrhagic Telangiectasia

Influence of Hypoxic Induced Factors in Patients With Hereditary Hemorrhagic Telangiectasia

RECRUITING
NCT04469517University Hospital, EssenStarted 2020-08-10
hypoxic induced factors
Other Disorders of Vestibular Function, BilateralBilateral Vestibular Deficiency (BVD)Gentamicin Ototoxicity

Vestibular Implantation to Treat Adult-Onset Bilateral Vestibular Hypofunction

RECRUITING
NCT05674786Phase NAJohns Hopkins UniversityStarted 2023-02-28
Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Other Disorders of Vestibular Function, BilateralBilateral Vestibular Deficiency (BVD)Gentamicin Ototoxicity

Vestibular Implantation in Older Adults

RECRUITING
NCT05676944Phase NAJohns Hopkins UniversityStarted 2023-04-11
Labyrinth Devices MVI™ Multichannel Vestibular Implant System
Non Small Cell Lung CancerEpidermal Growth Factor Receptor Gene MutationStage III Lung Cancer

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

RECRUITING
NCT06538038PrECOG, LLC.Started 2024-09-17
OsimertinibOsimertinib + Chemotherapy
Breast Cancer Susceptibility Gene (BRCA1) MutationBRCA2 MutationFear of Cancer Recurrence

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

NOT YET RECRUITING
NCT06817694Phase NACHU de Quebec-Universite LavalStarted 2025-06
Cognitive-behavioral group therapy
Shwachman-Diamond SyndromeSDSIBMF

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

RECRUITING
NCT06999954Shwachman-Diamond Syndrome Alliance IncStarted 2024-02-07
Heart Defects, CongenitalPulmonary Arterial HypertensionGenetic Testing

Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions

RECRUITING
NCT02691689Phase NAUniversitaire Ziekenhuizen KU LeuvenStarted 2015-11
Genetic testing
Breast CancerDepression

E-Mindfulness Approaches for Living After Breast Cancer

RECRUITING
NCT06748222Phase PHASE3NRG OncologyStarted 2025-06-12
Mindfulness (MAPs) Live OnlineMindfulness (MAPs) Digital AppMeditation Only Control Group
Hereditary Hemorrhagic Telangiectasia

Cardiac Evaluation in Hereditary Hemorrhagic Telangiectasia

NOT YET RECRUITING
NCT07101575Fondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-08-05
Transthoracic echocardiography
Hereditary CancerBreast CancerOvarian Cancer

The DIALOGUE Study: Swiss-Korean Billateral Collaboration

RECRUITING
NCT04214210Phase NAUniversity of BaselStarted 2022-04-15
Adapted Family Gene ToolkitTargeted intervention